Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Gastrointestinal oncology – what you need to know

Elizabeth Smyth and David Cunningham
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.12-6-575
Clin Med December 2012
Elizabeth Smyth
Department of Gastrointestinal Oncology, Royal Marsden Hospital Foundation Trust, Sutton, UK
Roles: Clinical Research Fellow
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: elizabeth.smyth@rmh.nhs.uk
David Cunningham
Department of Gastrointestinal Oncology, Royal Marsden Hospital Foundation Trust, Sutton, UK
Roles: Professor of Medical Oncology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading
Key Words
  • colorectal cancer
  • gastric cancer
  • hepatocellular cancer
  • oesophageal cancer
  • pancreatic cancer

Gastrointestinal (GI) cancers are common, comprising almost one-quarter of all cancers diagnosed in the UK annually.1 The most commonly encountered GI cancers are colorectal, oesophagogastric, pancreatic and hepatocellular carcinoma (HCC). Each tumour type demonstrates a distinct epidemiology, presentation, spectrum of clinical behaviour and requires a unique treatment approach, so they will be discussed separately.

Colorectal cancer

Colorectal cancer is the third most common cancer and the second leading cause of cancer death in the UK, accounting for 13% of new cancer cases annually. The incidence is strongly associated with age, rates increasing rapidly over the age of 50 with 72% diagnosed over the age of 65 years. Current lifetime risks for colorectal cancer in the UK are one in 15 and one in 19 for men and women respectively.1 The recent introduction of screening for colorectal cancer in the UK resulted in a temporary increase in incidence. However, following this, a trend towards earlier stage and less advanced disease has been observed in most pilot screening areas, with a corresponding decrease in colorectal-specific mortality.2 There is significant variation in colorectal cancer risk related to heterogeneity of epidemiological risk factors such as consumption of red meat, fibre and alcohol, and patterns of obesity and physical activity. Directly attributable genetic causes of colorectal cancer such as familial adenomatous polyposis and Lynch syndrome are responsible for a small number of cases (<5%), but less well-defined genetic syndromes may also play a significant role. Patients with multiple familial cases should also be considered for genetic referral and early colonoscopic screening programmes.3

Presentation

Colorectal cancer may present with a change in bowel habit, intestinal bleeding, abdominal pain, weight loss, obstructive symptoms or anaemia. Bright red blood per rectum is more commonly associated with left-sided tumours (rectum, sigmoid and descending colon), whereas right-sided tumours more commonly present with occult bleeding. Similarly, obstructive colon tumours more frequently occur in the left and sigmoid colon, whereas right-sided tumours are often more insidious in nature. Jaundice, hepatomegaly, ascites and pulmonary signs are indicative of advanced disease.

Investigation and staging

Clinical evaluation should include complete history (including family history) and physical examination, laboratory tests to include full blood count, electrolytes, liver function and carcinoembryonic antigen, in addition to full colonoscopy and computed tomography (CT) to evaluate for metastatic disease. Patients with rectal cancer should also undergo endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI) for local evaluation of rectal staging prior to initiating therapy.

Colorectal cancer staging is performed according to the tumour, node, metastasis (TNM) classification of the American Joint Commission on Cancer staging system or, more commonly (but less comprehensively), according to the Dukes classification system:

  • Dukes A tumours are restricted to, but do not fully penetrate, the bowel wall

  • Dukes B penetrate the bowel wall

  • Dukes C demonstrate locoregional lymph nodal spread, and

  • Dukes D are associated with distant metastasis.

Management

Surgery. The type of surgical resection is dictated by the location of the lesion within the bowel. Stage I lesions (equivalent to Dukes A) are managed with resection only. Patients with locally advanced rectal cancer benefit from local downstaging with 5-fluorouracil (5-FU)-containing chemoradiation prior to surgical resection.4

Chemotherapy. Following resection, consideration should be given to adjuvant chemotherapy to decrease the risk of recurrence due to residual microscopic disease.

For fit stage III (node-positive) patients (equivalent to Dukes C), adjuvant chemotherapy is routinely offered in the form of a six-month course of fluoropyrimidines (oral or intravenous) plus or minus oxaliplatin.5,6 For patients with stage III disease, the absolute risk reduction with combination chemotherapy is 8–13% (the incremental benefit due to oxaliplatin representing about 3–4%). The survival advantage associated with adjuvant chemotherapy declines with age and reduced benefit is seen for the addition of oxaliplatin in those over 70 years.

The general risk of recurrence is much lower for stage II (Dukes B) tumours (15–20%), depending on T stage and other adverse prognostic factors such as emergency presentation, lymphovascular invasion and lymph node yield. Accordingly, the benefit from adjuvant chemotherapy is less for these patients (absolute benefit approximately 3.5% and no additional gain with oxaliplatin). Stage II patients who display mismatch repair deficiency do not appear to benefit from adjuvant 5-FU-based chemotherapy and it is recommended that this status is checked prior to initiating therapy in this patient group.

Metastatic colorectal cancer

Patients who present with metastatic colorectal cancer may benefit from metastatectomy and surgical resection with curative intent if metastases are limited in number and amenable to surgery. However, such patients are in the minority and most patients with stage IV disease (equivalent to Dukes D) are treated with palliative systemic chemotherapy. Patients fit to be treated with combination chemotherapy and novel biologic agents targeting angiogenesis (bevacizumab) or the epidermal growth factor receptor (cetuximab or panitumumab) have a median survival of almost two years, representing almost a doubling of overall survival in the past decade.7,8

Additionally, local control of disease and chemotherapy-free intervals may be provided for selected patients with limited (usually single-organ) metastasis by non-surgical regional treatment approaches such as radiofrequency ablation (RFA) of lung and liver metastases or selective internal radiation therapy using yttrium microspheres injected into the hepatic arterial circulation (Fig 1).9,10

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Radiofrequency ablation (RFA) of colorectal liver metastasis. Axial T1-weighted delayed post-contrast images: (a) pre- and (b) post-RFA of a solitary liver metastasis. The RFA lesion encompasses the entire metastasis with a margin to achieve adequate ablation. The RFA defect has a clearly demarcated low signal intensity rim due to the presence of haemosiderin. The central coagulative necrosis returns high signal intensity on T1-weighted images.

Oesophagogastric cancer

Oesophageal cancer

Oesophageal cancer, of which there are about 8,000 cases in the UK annually, comprises two distinct disease entities:

  1. 1. Squamous cell carcinoma (SCC) of the oesophagus commonly occurs proximally and is strongly associated with social deprivation, alcohol and tobacco use. Its incidence has declined significantly in recent decades.

  2. 2. Adenocarcinoma occurs most often in the distal third of the oesophagus and is associated with obesity, reflux and a history of Barrett's oesophagus. Incidence rates have increased dramatically in western countries in the past 30 years, with UK rates now amongst the highest globally.1

Investigation. Oesophageal SCC and adenocarcinoma frequently present in a common manner with dysphagia and weight loss, but distinct treatment approaches are required. Patients with localised disease should undergo investigation with CT to evaluate for metastatic spread prior to consideration of a radical treatment approach. EUS is valuable both to determine the extent of local invasion and to evaluate suspicious lymph nodes using fine-needle aspirate. Fluorodeoxyglucose-positron emission tomography scan may also be useful to detect occult metastases not seen on CT in up to 15% of adenocarcinoma patients (Fig 2).

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Fluoro-deoxyglucose-positron emission tomography (a and c) demonstrates multiple bony metastases from oesophageal cancer not seen on computed tomography (b).

Management. Patients with SCC are treated with a combined platinum-based chemoradiation with curative intent. They may not require surgical resection if a complete pathological response is obtained at follow-up endoscopy.11,12

Adenocarcinoma is a less radiosensitive disease and more likely to be associated with occult distant metastatic spread. These patients appear to benefit less from a localised chemoradiotherapy approach. In the UK, most of them undergo pre-operative chemotherapy followed by surgical resection.14 Oesophagogastrectomy may be associated with significant complications and mortality in addition to substantial postoperative morbidity. Thus, surgery should be performed only on fit patients at high-volume surgical centres with appropriate expertise in order to minimise these risks.

Gastric cancer

Gastric cancer occurs in almost 8,000 patients per year in the UK. Adenocarcinoma of the cardia (upper third) of the stomach shares a common aetiology and incidence with adenocarcinoma of the distal oesophagus. Distal (antral) gastric cancers (which have decreased in incidence) are associated with Helicobacter pylori infection and dietary factors such as high intake of preserved or smoked foods and low intake of fruit and vegetables.

Investigation and staging. Staging of patients with gastric cancer is similar to that for oesophageal cancer, with the addition of pre-operative laparoscopy to detect occult peritoneal metastases prior to initiating treatment with curative intent.

Management. In the UK and Europe, fit patients with localised disease are treated with three cycles of cisplatin-based pre-operative chemotherapy and further cycles in the postoperative setting – an approach that has increased three-year survival from 23% to 36% compared with surgery alone.13 In the US, postoperative chemoradiation is commonly employed but, given the morbidity associated with gastrectomy, fewer patients are suitable for this approach.

Unfortunately, most patients in the UK presenting with oesophagogastric cancer have advanced disease not amenable to surgical resection. Fit patients with metastatic or unresectable disease are treated with combination cisplatin-based chemotherapy, most often epirubicin, cisplatin and capecitabine (EOX), and have a median overall survival of 9–11 months.14 The addition of the anti-HER2 monoclonal antibody trastuzumab to chemotherapy for the approximately 20% of patients who overexpress the HER2 protein has led to significant increases in survival for this population.15 Symptomatic control of dysphagia using oesophageal stents also remains a useful treatment option.

Pancreatic cancer

Cancer of the pancreas is diagnosed in over 8,000 patients per year in the UK and remains one of the most lethal malignancies, with overall five-year survival below 5%.1 These poor survival outcomes reflect both the infiltrative nature of the disease, which is frequently unresectable or metastatic at presentation (only 10–15% of patients are operable), and the underlying chemorefractory status of the tumour. Patients may present with weight loss, abdominal or back pain, or painless obstructive jaundice which may be relieved by biliary stent placement.

Key points

Colorectal cancer is the third most common cancer in the UK and the second leading cause of cancer death. Recently initiated screening programmes demonstrate early signs of decrease in colorectal cancer-specific mortality

Survival for patients with metastatic colorectal cancer treated with cytotoxic chemotherapy and biologic agents now extends up to two years (almost doubled in the last decade)

Careful patient selection and centralisation of surgery in high-volume centres are essential to optimise surgical outcomes for patients undergoing oesophagogastrectomy. Neoadjuvant, peri-operative or postoperative treatment increases survival for patients with operable gastro-oesophageal cancer

Early involvement of palliative care services for patients with metastatic pancreatic cancer is advised in order to improve both symptom control and quality of life

Patients with unresectable or metastatic hepatocellular carcinoma with preserved liver function may benefit from treatment with the oral anti-angiogenic agent sorafenib

Investigation

Specialised pancreatic protocol CTs are necessary to delineate the anatomy of the coeliac axis in order to determine resectability.

Management

Patients with operable disease are treated with postoperative adjuvant gemcitabine chemotherapy, leading to median survival of 23 months.16 Patients with locally advanced unresectable non-metastatic pancreatic cancer are treated with combination chemotherapy, possibly followed by chemoradiation. Those with metastatic disease are treated with chemotherapy alone.17 Their survival with current combination chemotherapy regimens ranges from 6–12 months.18,19 Because of issues surrounding symptom control and nutrition, early interaction with palliative care services is advised for these patients.

Hepatocellular carcinoma

Although rates of HCC remain low overall in the UK (about 4,000 cases per year), the incidence has trebled in the past 30 years. Risk factors include hepatitis B and C infection, high alcohol intake, smoking, obesity, diabetes, haemochromatosis and non-alcoholic steatohepatitis. Presentation is frequently non-specific, with abdominal pain, fullness, weight loss and anorexia, or an abdominal mass. Signs of chronic liver disease may also be present.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Treatment of gastrointestinal cancers.

Investigation

Assessment of liver function is a key component in the evaluation of the patient with HCC as this will impact significantly on treatment choices. Serum alpha-fetoprotein is also a useful marker in over half of patients. Triphasic CT, gadolinium-enhanced MRI and ultrasound may all be used to assess resectability.

Management

Partial hepatic resection may be performed for patients with solitary lesions, no evidence of vascular invasion or portal hypertension, and adequate hepatic function. Given the risk of tumour seeding, no biopsy should be taken provided that the tumour meets radiologic criteria for diagnosis.

If resection is not possible, or the patient has compromised liver function but meets the Milan criteria for transplant (a solitary lesion <5 cm or up to three lesions with none >3 cm in size, with no evidence of vascular invasion or regional or distant metastases), orthotopic liver transplantation may be performed.

Local ablation methods such as RFA or transarterial chemoembolisation may be considered for patients who do not meet resection or transplant criteria but only have hepatic disease.

Until recently, treatment options for patients presenting with or developing metastatic disease were extremely limited as HCC does not display chemosensitivity. However, the oral anti-angiogenic tyrosine kinase inhibitor sorafenib has improved median overall survival to almost one year (survival on sorafenib is three months longer than on placebo), but is suitable only for patients with relatively preserved liver function.20

  • © 2012 Royal College of Physicians

References

  1. ↵
    1. Cancer Research UK
    . Cancer incidence for common cancers 2009. www.cancerresearchuk.org/cancer-info/cancerstats/incidence/commoncancers/ [Accessed 31 October 2012].
  2. ↵
    1. McClements PL
    Madurasinghe V Thomson CS, et al. Impact of the UK colorectal cancer screening pilot studies on incidence, stage distribution and mortality trends. Cancer Epidemiol 2012; 36:e232–42.doi:10.1016/j.canep.2012.02.006
    OpenUrlCrossRefPubMed
  3. ↵
    1. Cairns SR
    Scholefield JH Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59:666–89.doi:10.1136/gut.2009.179804
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Bosset JF
    Collette L Calais G, et al. EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355:1114–23.
    OpenUrlCrossRefPubMed
  5. ↵
    1. André T
    Boni C Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109–16.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Quasar Collaborative Group Gray R Barnwell J McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370:2020–9.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Saltz LB
    Clarke S Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26:2013–9.doi:10.1200/JCO.2007.14.9930
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Douillard JY
    Siena S Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010; 28:4697–705.doi:10.1200/JCO.2009.27.4860
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Ruers T
    Punt C Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 2012; 23:2619–2626.doi:10.1093/annonc/mds053
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Hendlisz A
    Van den Eynde M Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28:3687–94.doi:10.1200/JCO.2010.28.5643
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Herskovic A
    Martz K al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326:1593–8.doi:10.1056/NEJM199206113262403
    OpenUrlCrossRefPubMed
  12. ↵
    1. Bedenne L
    Michel P Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25:1160–8.doi:10.1200/JCO.2005.04.7118
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Cunningham D
    Allum WH Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11–20.doi:10.1056/NEJMoa055531
    OpenUrlCrossRefPubMed
  14. ↵
    1. Cunningham D
    Starling N Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36–46.doi:10.1056/NEJMc0911925
    OpenUrlCrossRefPubMed
  15. ↵
    1. Bang YJ
    Van Cutsem E Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687–97.doi:10.1016/S0140-6736(10)61121-X
    OpenUrlCrossRefPubMed
  16. ↵
    1. Oettle H
    Post S Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267–77.doi:10.1001/jama.297.3.267
    OpenUrlCrossRefPubMed
  17. ↵
    1. Huguet F
    Girard N Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009; 27:2269–77.doi:10.1200/JCO.2008.19.7921
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Conroy T
    Desseigne F Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817–25.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Cunningham D
    Chau I Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27:5513–8.doi:10.1200/JCO.2009.24.2446
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Llovet JM
    Ricci S Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378–90.doi:10.1056/NEJMoa0708857
    OpenUrlCrossRefPubMed
    1. Cheng AL
    Kang YK Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25–34.doi:10.1016/S1470-2045(08)70285-7
    OpenUrlCrossRefPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Gastrointestinal oncology – what you need to know
Elizabeth Smyth, David Cunningham
Clinical Medicine Dec 2012, 12 (6) 575-579; DOI: 10.7861/clinmedicine.12-6-575

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Gastrointestinal oncology – what you need to know
Elizabeth Smyth, David Cunningham
Clinical Medicine Dec 2012, 12 (6) 575-579; DOI: 10.7861/clinmedicine.12-6-575
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Colorectal cancer
    • Oesophagogastric cancer
    • Pancreatic cancer
    • Hepatocellular carcinoma
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Investigation of iron deficiency anaemia 
  • Non-alcoholic fatty liver disease
  • CME Gastroenterology (113045): self-assessment ­questionnaire
Show more CME Gastroenterology

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians